- Home
- GLMD vs KZIA Comparison
GLMD vs KZIA Comparison
Compare GLMD & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- KZIA
- Stock Information
- Founded
- GLMD 2000
- KZIA 1994
- Country
- GLMD Israel
- KZIA Australia
- Employees
- GLMD N/A
- KZIA N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- KZIA Health Care
- Exchange
- GLMD Nasdaq
- KZIA Nasdaq
- Market Cap
- GLMD 8.0M
- KZIA 9.0M
- IPO Year
- GLMD 2014
- KZIA 1999
- Fundamental
- Price
- GLMD $1.59
- KZIA $7.20
- Analyst Decision
- GLMD Hold
- KZIA Strong Buy
- Analyst Count
- GLMD 1
- KZIA 3
- Target Price
- GLMD N/A
- KZIA $16.00
- AVG Volume (30 Days)
- GLMD 81.5K
- KZIA 299.1K
- Earning Date
- GLMD 11-13-2025
- KZIA 11-14-2025
- Dividend Yield
- GLMD N/A
- KZIA N/A
- EPS Growth
- GLMD N/A
- KZIA N/A
- EPS
- GLMD N/A
- KZIA N/A
- Revenue
- GLMD N/A
- KZIA $1,549,158.00
- Revenue This Year
- GLMD N/A
- KZIA N/A
- Revenue Next Year
- GLMD N/A
- KZIA $49.25
- P/E Ratio
- GLMD N/A
- KZIA N/A
- Revenue Growth
- GLMD N/A
- KZIA 248983.08
- 52 Week Low
- GLMD $1.15
- KZIA $2.86
- 52 Week High
- GLMD $4.81
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- GLMD 58.87
- KZIA 43.08
- Support Level
- GLMD $1.35
- KZIA $6.20
- Resistance Level
- GLMD $1.63
- KZIA $7.61
- Average True Range (ATR)
- GLMD 0.09
- KZIA 0.48
- MACD
- GLMD 0.02
- KZIA -0.06
- Stochastic Oscillator
- GLMD 76.67
- KZIA 47.57
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.